Background: Atrial fibrillation (AF) is a known risk factor for stroke disease and anticoagulation has a relative risk reduction of 60 -70% for the prevention of stroke. Not all patients with known AF receive anticoagulation. In addition, 20% of stroke patients with AF have strokes unrelated to their AF. Methodology: In 2016, 383 patients were admitted to our hospital with a confirmed stroke. We compared data on patients who were admitted with confirmed (known) AF and those who were newly identified as AF. Results: A total of 101 (26%) patients had AF. 67 (66.3%) patients had known AF. Comparing the known and new AF, there was no difference in age or sex distribution.
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39 (58%) of the known AF were on an oral anticoagulant (OAC); 18 (46.2%) of these patients were on warfarin with a mean INR on admission of 1.95. 21 (54%) were on a direct oral anticoagulant (DOAC).
15 (22%) of the known AF presented with an intra-cerebral haemorrhage (ICH) compared with 2 (5.8%) in the new AF population. 10 (66.7%) of the ICHs in the known AF cohort were on a DOAC compared with 3 (20%) on warfarin.
Comparing outcomes, 40-patients (59.7%) had a good outcome (discharge home) in the known AF group compared to 21 (61.7%) in the new AF. 27 (40.3%) had a bad outcome (discharge to nursing home/death)in the known AF group compared to 13 (38.2%) in the new AF. This shows no significant difference overall, however, there was a higher rate of mortality in the known-17 (25.4%) compared to the new AF-2 (5.9%) (p.0001). Conclusion: A significant number of stroke patients have AF on admission and a third are new cases. For those patients with known AF, a significant number are still not anticoagulated in the community. A higher number of ICHs were seen in the known AF group and more commonly in those on a DOAC. The known AF group is at a higher risk of a bad outcome post stroke.
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